ArticleACS omega2025
Engineering Extended Release Profiles for Biologic Formulations via Chemical Cross-Linking of Poloxamer 407 Hydrogels.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydrogels, networks of hydrophilic polymers known for their water retention capacity, biodegradability, and biocompatibility, are ideal for the sustained and extended delivery of biologics. Because in situ hydrogels can form at the administration site in response to external stimuli, they can provide noninvasive and localized delivery of biotherapeutics. In particular, poloxamer 407 (P407), an "A-B-A" triblock copolymer, composed of hydrophilic poly-(ethylene oxide) (block A) and hydrophobic poly-(propylene oxide) (block B), exhibits reversible thermal property: liquid at room temperature and gelling at elevated temperatures. This characteristic, combined with its low toxicity and excellent chemical compatibility, makes P407 an attractive polymer for drug delivery applications. However, its low mechanical strength and weak gel stability have limited its broader use in therapeutic applications. To address this challenge, chemically cross-linked P407 hydrogels were developed using acrylate-modified P407 and thiol-terminated eight-arm polyethylene glycol with two different molecular weights (MWs) via Michael-type addition. Chemical cross-linking enhanced the mechanical strength of P407 hydrogels, enabling extended in vitro release of bovine serum albumin (BSA), human plasma immunoglobulin G antibody (IgG), and adalimumab for up to 70 days with tunable release kinetics profile. Biophysical and functional characterization via circular dichroism, size exclusion chromatography, capillary electrophoresis-sodium dodecyl sulfate, and enzyme-linked immunosorbent assay indicated that the hydrogels did not adversely affect the structural conformation, stability, and in vitro potency of the encapsulated biologics. This study highlights improved P407 hydrogel stability and tunable release profiles by incorporating acrylate reactive cross-linkers with two different MWs, providing insights for the application of sustained and controlled release of biologic.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.